H.R. 4384 (112th): Patient Safety and Drug Labeling Improvement Act

Introduced:
Apr 18, 2012 (112th Congress, 2011–2013)
Status:
Died (Referred to Committee)
Sponsor
Chris Van Hollen Jr.
Representative for Maryland's 8th congressional district
Party
Democrat
Text
Read Text »
Last Updated
Apr 18, 2012
Length
2 pages
Related Bills
S. 2295 (Related)
Patient Safety and Generic Labeling Improvement Act

Referred to Committee
Last Action: Apr 18, 2012

 
Status

This bill was introduced on April 18, 2012, in a previous session of Congress, but was not enacted.

Progress
Introduced Apr 18, 2012
Referred to Committee Apr 18, 2012
 
Full Title

To permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.

Summary

No summaries available.

Cosponsors
1 cosponsors (1D) (show)
Committees

House Energy and Commerce

Health

The committee chair determines whether a bill will move past the committee stage.

 
Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.

Widget

Get a bill status widget for your website »

Citation

Click a format for a citation suggestion:

Notes

H.R. stands for House of Representatives bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.


4/18/2012--Introduced.
Patient Safety and Drug Labeling Improvement Act - Amends the Federal Food, Drug, and Cosmetic Act to allow the holder of an approved abbreviated new drug application (generic drug approval) to change the labeling of a drug so approved in the same manner authorized by regulation for the holder of an approved new drug application.
Allows conforming changes to be ordered to the labeling of the equivalent listed drug and each drug approved under the abbreviated new drug application process that corresponds to such listed drug.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.


No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of H.R. 4384 (112th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus